Golvatinib

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C82363

928037-13-2

C33H37F2N7O4

C82363

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.

Golvatinib

516Z3YP58E

E7050

1,1-cyclopropanedicarboxamide, N-(2-fluoro-4-((2-(((4-(4-methyl-1-piperazinyl)-1-piperidinyl)carbonyl)amino)-4-pyridinyl)oxy)phenyl)-N'-(4-fluorophenyl)-

Golvatinib

GOLVATINIB

c-Met/VEGFR-2 Kinase Inhibitor E7050

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C18186

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C28496

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Golvatinib

c-Met_VEGFR_Kinase_Inhibitor_E7050

Golvatinib

640626

640626

640626

Golvatinib

Thesaurus:C82363

Golvatinib

Pharmacologic Substance

C3642430

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1404

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129825